Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticancer gelatin microspheres with multiple functions.

C H Yan1, X W Li, X L Chen

  • 1Chengdu Institute of Organic Chemistry, Academia Sinica, Chengdu, China.

Biomaterials
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Role of lymphatic network in cardiac repair post myocardial infarction].

Zhonghua xin xue guan bing za zhi·2026
Same author

[Haploidentical hematopoietic stem cell transplantation for advanced myelodysplastic syndrome patients with recurrent genetic abnormalities].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same author

[Screening and identification of vascular calcification-associated genes: implication of thymidine kinase 1].

Zhonghua xin xue guan bing za zhi·2025
Same author

[Renal solitary fibrous tumors: a clinicopathological analysis of five cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2025
Same author

[Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2025
Same author

[Integrating single-cell analysis and epharmalib reverse virtual screening to predict novel vascular endothelial cell targets of dapagliflozin in treating diabetic cardiomyopathy].

Zhonghua xin xue guan bing za zhi·2025
Same journal

A sonosensitizing hydrogel with tumour-confined stability for intrinsically targeted sonodynamic therapy.

Biomaterials·2026
Same journal

Multidimensional intestinal barrier repair strategies for alleviating inflammatory bowel disease and gut-liver axis-associated metabolic liver disease.

Biomaterials·2026
Same journal

A dual-twisted molecular strategy achieves dramatic quantum-yield enhancement in NIR-II AIEgen for high-performance bioimaging.

Biomaterials·2026
Same journal

An oxygen-glucose co-releasing platform fostering dental pulp regeneration by driving metabolic recovery of stem cells.

Biomaterials·2026
Same journal

Prodrug-decorated 2D hafnium sulfide nanoplatelets as "amplify-and-arrest" platforms for radiosensitization and homologous recombinant inhibition in solid tumor.

Biomaterials·2026
Same journal

In-situ cascade assembled peptide-drug conjugate for the treatment of bladder cancer by enhancing membrane-entry and lysosome destabilization.

Biomaterials·2026
See all related articles

Biodegradable gelatin microspheres loaded with mitomycin C and iodine-131 offer targeted liver cancer treatment. These microspheres provide sustained drug release and localized radiotherapy within hepatic arteries for at least one month.

Area of Science:

  • Biomaterials science
  • Radiochemistry
  • Oncology

Background:

  • Biodegradable hydrophilic gelatin microspheres (GM) are suitable for drug delivery.
  • Hepatic intra-arterial infusion requires effective drug carriers for localized chemotherapy and radiotherapy.

Purpose of the Study:

  • To develop and characterize 131I-labelled mitomycin C-GM (131I-MMC-GM) for combined chemotherapy and radiotherapy.
  • To evaluate the in vivo behavior and in vitro drug release of 131I-MMC-GM after hepatic intra-arterial infusion.

Main Methods:

  • Gelatin microspheres (GM) were prepared by cross-linking gelatin with glutaraldehyde.
  • Mitomycin C (MMC) and iodine-131 (131I) were bound to GM.
  • In vitro drug release was quantified using dynamic dialysis.

Related Experiment Videos

Main Results:

  • The 131I-MMC-GM demonstrated accumulation and embolization within hepatic arteries.
  • The microspheres remained in the hepatic arteries for at least one month.
  • Various effects on liver cells were observed post-infusion.

Conclusions:

  • 131I-MMC-GM is a promising dual-modality therapeutic agent for liver cancer.
  • The microspheres provide sustained local drug delivery and radiotherapy.
  • Further investigation into liver cell effects is warranted.